Altamira Therapeutics announced that its associate company, Altamira Medica, has received a notice of allowance from the Japan Patent Office covering Bentrio nasal spray.
The patent strengthens intellectual property protection in Japan — one of the world’s largest and highest-prevalence allergic rhinitis markets.
Product Overview: Drug-Free Nasal Protection
Bentrio is an over-the-counter, drug-free, preservative-free nasal spray approved or cleared in multiple countries for:
- Prophylaxis of allergic rhinitis
- Treatment support in allergic rhinitis
- In certain jurisdictions, protection against airborne viruses
Unlike antihistamines or corticosteroids, Bentrio works via a physical mechanism.
Triple Mode of Protection:
- Formation of a protective gel barrier on nasal mucosa
- Trapping of airborne allergens
- Moisturization of the mucosal surface
This mechanical mode of action positions Bentrio as a medical device rather than a pharmaceutical.
Strategic Importance of Japan
Japan represents a high-value target market due to:
- Extremely high allergic rhinitis prevalence (~50% population estimates)
- Significant incidence of Japanese cedar pollinosis
- Established OTC consumer health infrastructure
Securing patent protection in Japan:
- Extends lifecycle protection
- Supports premium positioning
- Enhances partner negotiation leverage
- Protects against local generic device replication
Given the scale of seasonal pollen exposure in Japan, commercial opportunity is substantial.
Clinical Evidence: NASAR Study
The largest clinical trial, NASAR (n=100 seasonal allergic rhinitis patients), compared Bentrio to saline over two weeks.
Key findings:
- Statistically significant reduction in rTNSS (p = 0.013)
- Highly significant improvement in quality of life (p < 0.001)
- Fewer rescue medication uses
- Increased symptom-free days
- Safety profile comparable to saline
While modest in scale, these results support differentiation versus simple saline sprays.
Competitive Positioning
Bentrio competes in a crowded allergic rhinitis landscape that includes:
- Oral antihistamines
- Intranasal corticosteroids
- Leukotriene inhibitors
- Allergen immunotherapy
Its differentiation lies in:
- Drug-free positioning
- Favorable safety profile
- Suitability for pediatric and polypharmacy populations
- Complementary use alongside pharmacologic treatments
In markets with strong consumer health segments, mechanical barrier devices can capture meaningful niche share.
Broader Corporate Context
Altamira Therapeutics’ core strategic focus is its xPhore peptide-based nanoparticle platform for nucleic acid delivery.
This platform supports modalities including:
- siRNA
- mRNA
- circRNA
- DNA
The Bentrio business provides:
- Diversified revenue potential
- Regulatory and commercialization expertise
- IP portfolio strengthening
However, long-term valuation likely centers on its nucleic acid delivery partnerships rather than OTC nasal products.
Strategic Takeaway
The Japanese patent allowance for Bentrio:
- Secures IP protection in a high-prevalence allergy market
- Reinforces commercialization potential in Asia
- Enhances asset defensibility
While not a breakthrough pharmaceutical innovation, Bentrio represents a differentiated consumer-health device with clinically supported efficacy and strong positioning in allergy-heavy markets.
For Altamira, the milestone strengthens near-term commercial optionality while its nucleic acid delivery platform remains the longer-term strategic growth engine.